Shraddha Chaugule of Astro Health Inc - Luminary

Join us for a private Family Office Insights Webinar to understand how Astro Health is transforming healthcare delivery and treatment outcomes with evidence-based artificial intelligence AI. This is an exclusive opportunity to hear directly from founder Dr. Shraddha Chaugule about the world’s first clinically validated multi-agentic AI digital health platform delivery system for stress, substance use disorder management, and longevity.

With proven clinical validation from the American Psychiatric Association (APA), engineering platform validation from the Institute of Electrical and Electronic Engineers (IEEE), and a pilot program clinical study with the Los Angeles General Medical Center, Astro Health is positioned to transform healthcare delivery, improve outcomes for those with substance use disorder, and extend the quality of life for people with dementia.

We invite you to learn how you can support and invest in frontier healthcare innovation solving the most critical healthcare challenges. Dr. Chaugule is a recognized digital health and outcomes research expert, and has collaborated with the Centers for Disease Control and Prevention (CDC), the RAND Corporation, and the Children’s Hospital Los Angeles.

December 04, 2025 from 2:15pm to 3:15pm EST

Investors Only Please!

About Astro Health Inc

Astro Health is the world’s first company with an AI-enabled multi-agentic clinically validated digital health treatment delivery platform for substance use disorder and longevity.

With over 40 million people with substance use disorder in the U.S., only 2.7 million people receive treatment, with 82% of prescribers concentrated in urban areas. Of those receiving treatment, a third discontinue, leading to relapses, ER visits, and hospitalizations, resulting in $500 billion in healthcare costs to the U.S. economy. The highly intelligent Astro X platform supports patients in real time and prevents relapses by utilizing Large Language Models (LLMs) and multi-modal data intelligence. The AI system’s adaptive framework utilizes generative AI to evolve alongside the user's needs, offering real-time patient monitoring and feedback, thus removing significant administrative burden from the healthcare system. This is the only AI system in the world with high credibility and both clinical and engineering validation. The system’s 360 degree model includes human-in-the- loop on-demand psychiatrists, licensed therapists, and health advocates to ensure timely care. Empirical validation of the platform with data from 4,000 individuals demonstrates approximately 90% validation accuracy, thus positioning it as a significant integrated treatment delivery platform application for stress and substance use disorder. A clinical pilot program has been initiated at the Los Angeles General Medical Center for platform validation in human subjects.

The company’s second AI platform will address the problem of caregiving for people living with dementia and Parkinson’s, which is an approximately $230 billion a year problem in the U.S., arising because of changes in functioning in patients that impact the ability to look after oneself, and can lead to increased anxiety-and-loss of confidence. To address this problem and its economic impact, this novel integrated AI digital healthcare support system will help improve and relearn neuropsychological and functional skills related to language, information processing, mental health status, visuospatial skills, and mobility, improving quality of life for people living with dementia. The platform’s beta model was developed in Sportstech, and Astro Health is currently raising funds for their patient validation study.

Target Audience
Substance Use Disorder Management Platform – Value-based reimbursement model for health systems, employer-covered health insurance companies, Medicaid, and country-level universal health systems such as NICE (UK), TLV (Sweden), GBA & IQWIG (Germany), and HAS (France).

Enterprise Stress Platform – Employers purchase subscriptions to reduce healthcare spending, turnover rate and improve employee productivity. Tier one will be under HR system, and tier two will involve human-in-loop licensed therapists provided as part of employee benefits.

Longevity AI Platform – B2C, Medicare, nursing homes, the United States Department of Veterans Affairs (VA), and TRICARE for injured war veterans and military members

Differentiators
✅ Unique technical founding team with rare cross-domain expertise
• Shraddha Chaugule, PhD (Founder & CEO): Highly specialized in outcomes research, digital health and behavioral economics. Exceptional technical founder with strong scientific credibility and research with the CDC and RAND w/ multiple publications.
• Ian Thornell (CTO & Founding AI Engineer): M.S. in AI from Oxford Brookes. Deep AI, autonomous systems, and wearables experience, with strong execution capability and real-time applications. Strong applied research and elite athletic discipline.
• Dr. Eric Hsieh (Clinical Research Principal Investigator): Senior faculty leader at the University of Southern California’s Keck School of Medicine. Numerous teaching and research awards, with a strong history of clinical validation and credibility.
• Indiana University academic AI partner with a world-class research edge: DARPA and NSF-funded projects.
✅ Clear competitive IP moat with technical strength and strong differentiation
• Unique: Proprietary multi-modal data integration, LLMs, and human-in-loop
• Engineering breakthrough: Individualized stressor detection (vs cluster) and contextual AI
• Strong IP: Real-time, adaptive interventions and feedback loops
• Technical rigor: Data architecture and validation work accepted at IEEE’s International Conference on Algorithms, Computing, and Artificial Intelligence (ACAI)
✅ Market validation and traction
• Clinical validation with the American Psychiatric Association (APA) conference presentation (May 2025)
• Pilot program launched with Los Angeles General Medical Center for real-world platform validation; ongoing discussions with credible partners
• Technical engineering validation from IEEE with ACAI conference presentation (Dec 2025).
✅ Massive unmet market needs (stress, substance use disorder, longevity).
Well-defined problems with clear economic impact.
• Stress and mental health B2B enterprises: $300B TAM, $15B SOM.
• Employer-covered health insurance Substance Use Disorder (US): $35.5B SAM, $3.5B SOM.
• Future market massive and growing (longevity, Parkinson's, Alzheimer's): ~12M unpaid caregivers in the U.S., costing $230B annually.
✅ Clear revenue models (SaaS and insurance).

Business Status
Astro Health was founded in San Francisco in August of 2023 after understanding the enormity of Substance Use Disorder and Mental Health problem post COVID arising high rates of treatment discontinuation and from the lack of access to healthcare in rural areas and underserved communities. As an outcomes scientist, founder Dr. Shraddha Chaugule, wanted to develop low-cost technologies that will improve treatment adherence and reduce relapse related adverse events. So, she leaned into Artificial Intelligence to design a highly intelligent digital health platform with real-time monitoring, live patient feedback and treatment delivery to improve outcomes and reduce administrative burden.
Astro X platform’s validation work was recognized by the American Psychiatric Association in May 2025 while the platform’s engineering data architecture and ground-breaking individual level detection technology will be presented at the upcoming IEEE conference presentation in Dec 2025. Based on this, a pilot program with LA General Medical Center was secured and work towards getting clinical study IRB approval for real-world platform validation has been completed.
Looking ahead, Astro Health is expanding efforts to scale, deepen engagement with health systems, and drive transformation of treatment delivery in the US delivering real impact via evidence-based sustainable solutions & treatment delivery powered by AI while being rooted in clinical and engineering research & validation. Their second integrated novel AI digital health care-support system will help improve functioning and extend independence in people living with Parkinson’s and Dementia. Beta model has been developed in Sportstech with direct application in Parkinson’s; currently the company is raising funds for patient validation study.

Funding Status
Internally, Astro Health was able to bootstrap work worth ~$1.5 million because of the super technical founding team. This work included data architecture design, platform validation, acceptance from top clinical and engineering organizations such as American Psychiatric Association and IEEE, securing pilot program partnership with LA General Medical Center, developing the clinical protocol and then securing tentative IRB approval. The wire framework is complete and with additional hiring the build will be complete for system integration.
Astro Health is now raising $5 million late SEED round via YC SAFE Notes preferably with the option of convertible notes if requested by investors for 18 months runway for two clinical programs at LA General Medical Center. More specifically, the first clinical study will involve real-world validation of stress and substance use disorder AI platform and the second study will involve precision care-support system longevity platform validation for Dementia and Parkinson’s patients. The funds will also go towards additional hiring and scaling.

Team

Shraddha Chaugule B.Pharm, MS, PhD

Founder, CEO, and Chief Health Outcomes Scientist

Shraddha is a well-respected behavioral economics and digital health researcher with (peer-reviewed publications) and specializes in the integrated fields of outcomes research, health economics, machine learning, pricing, and health policy. Shraddha has industry experience as a digital health global market access strategist with a successful track record of achieving access for technologies with Medicaid and, employer-covered health insurance in countries such as the UK, Canada, Australia, and more the UK, Italian provinces.

As a researcher, Shraddha has deep training and expertise in designing healthcare treatment interventions aimed at improving outcomes and generating cost -savings for health systems. During her doctoral program at the University of Southern California, Shraddha was awarded a dissertation fellowship by the Children’s Hospital Los Angeles. She has collaborated with the CDC, the RAND Corporation, and the federal government for research, resulting in several peer- reviewed publications.

Ian Thornell, BS, MSc in AI
Founding AI Engineer and CTO
Ian is a D1 rowing athlete from Boston University with a BS in Computer Science and Physics. He recently completed his MSc in AI from Oxford Brookes University in the UK.
Ian has deep experience and expertise in Sportstech and digital health. He is specialized in ML, data mining, data science, statistical modeling and autonomous systems. He is applied and has deep experience in developing and launching AI applications as well as building wearables. At Boston University, he did spatial body mapping to create an AI application to improve his rowing performance. This forms the basis of our Dementia AI platform. He also developed a reinforcement learning AI application for athletes in rehabilitation. At Astro Health, Ian heads AI and he himself performed the platform validation work which has been accepted at one of the top 3 IEEE Artificial Intelligence conferences with upcoming presentation in Dec 2025.

Clinical Research Principal Investigator Pilot Programs
Dr. Eric Hsieh
Dr. Hsieh is the Clinical Associate Professor of Medicine at University of Southern California’s Keck School of Medicine with a joint appointment as the Director of Residency Program at the LA General Medical Center (part of USC Health System). In 2010, Dr. Hsieh was awarded Arnold P. Goldstein Foundation’s Leonard Tow Humanism in Medicine Award. He also has numerous teaching awards and several peer reviewed research publications in top journals such as JAMA, J Gen Intern Me and Clin Case Rep.
Dr. Hsieh is the principal clinical study investigator for Astro Health’s real-world platform validation studies at LA General Medical Center.

Dr. Kristina Lerman
AI Research Partner R&D
Kristina Lerman is a Dr. Lerman's early career was marked by receiving substantial grants from the National Science Foundation (NSF), Defense Advanced Research Projects Agency (DARPA), and the Information Sciences Institute (ISI). Her empirical and experimental research has crucially highlighted the role of cognitive biases in interpreting both individual and collective behavior online. An active contributor to the social computing research sphere, Dr. Lerman has held positions of leadership such as chairing prominent conferences including SocInfo’14, SocialCom’14, Hypertext’13, and serving as a senior program committee member for ICWSM and IJCAI.
At Astro Health, we believe in collaborating with academic institutions and we are partnering with Dr. Lerman for 10% of our engineering work for research & development of advanced AI capabilities.

Alert & disclosure: Family Office Insights, BavelasGroup and/or an affiliates or assigns does not offer or give medical, financial or investment advice, or offer or suggest or recommend securities or any other investment for sale or otherwise and is not a broker dealer. As is our standard policy, we will with pleasure reschedule any service with best efforts issuing FOI services credit only. Anyone considering deployment of capital will likely be well served by seeking advice from a qualified professional. I love you.

All rights reserved. Copyright © 2025 & Forever Family Office Insights